Renal artery stenosis: Cost-effectiveness of diagnosis and treatment

Radiology

Volumn 244, Issue 2, 2007, Pages 505-513

  Van Helvoort Postulart, Debby ^a   Dirksen, Carmen D ^a   Nelemans, Patricia J ^b   Kroon, Abraham A ^a,c   Kessels, Alfons G H ^a   De Leeuw, Peter W ^a,c   Vasbinder, G Boudewijn C ^a   Van Engelshoven, Jos M A ^a,c   Hunink, M G Myriam ^d,e  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC IMAGING; DIASTOLIC BLOOD PRESSURE; DIGITAL SUBTRACTION ANGIOGRAPHY; HUMAN; IMAGE ANALYSIS; KIDNEY ARTERY STENOSIS; MONEY; MONTE CARLO METHOD; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RENOVASCULAR HYPERTENSION; REVASCULARIZATION;

ANGIOGRAPHY, DIGITAL SUBTRACTION; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DIAGNOSTIC IMAGING; FEMALE; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MARKOV CHAINS; MIDDLE AGED; MONTE CARLO METHOD; QUALITY-ADJUSTED LIFE YEARS; RENAL ARTERY OBSTRUCTION; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34447518938     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2442060713     Document Type: Article

References (56)

1. Hessel SJ, Adams DF, Abrams HL. Complications of angiography. Radiology 1981;138: 273-281.
2. Waugh JR, Sacharias N. Arteriographic complications in the DSA era. Radiology 1992;182:243-246.
3. Young N, Chi KK, Ajaka J, McKay L, O'Neill D, Wong KP. Complications with outpatient angiography and interventional procedures. Cardiovasc intervent Radiol 2002;25:123-126.
4. Rudnick MR, Berns JS, Cohen RM, Goldfarb S. Nephrotoxic risks of renal angiography: contrast media-associated nephrotoxicity and atheroembolism - a critical review. Am J Kidney Dis 1994;24:713-727.
5. Cochran ST, Bomyea K, Sayre JW. Trends in adverse events after IV administration of contrast media. AJR Am J Roentgenol 2001; 176:1385-1388.
6. Thomson HS, Morcos SK; and Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). In which patients should serum creatinine be measured before iodinated contrast medium administration? Eur Radiol 2005;15:749-754.
7. Vasbinder GB, Nelemans PJ, Kessels AC, et al. Accuracy of computed tomographic angiography and magnetic resonance angiography for diagnosing renal artery stenosis. Ann Intern Med 2004;141:674-682.
8. Working Group on Renovascular Hypertension. Detection, evaluation, and treatment of renovascular hypertension: final report. Arch Intern Med 1987;147:820-829.
9. Webster J, Marshall F, Abdalla M, et al; and the Scottish and Newcastle Renal Artery Stenosis Collaborative Group, Randomised comparison of percutaneous angioplasty vs continued medical therapy for hypertensive patients with atheromatous renal artery stenosis. J Hum Hypertens 1998;12:329-335.
10. van de Ven PJ, Kaatee R, Beutler JJ, et al. Arterial stenting and balloon angioplasty in ostial atherosclerotic renovascular disease: a randomised trial. Lancet 1999;353:282-286.
11. van Jaarsveld BC, Krijnen P, Pieterman H, et al; and the Dutch Renal Artery Stenosis Intervention Cooperative Study Group. The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. N Engl J Med 2000;342:1007-1014.
12. Vasbinder GB, Nelemans PJ, Kessels AG, Kroon AA, de Leeuw PW, van Engelshoven JM. Diagnostic tests for renal artery stenosis in patients suspected of having renovascular hypertension: a meta-analysis. Ann Intern Med 2001;135:401-411.
13. Lawrence V, Matthai W, Hartmaier S. Comparative safety of high-osmolality and low-osmolality radiographic contrast agents. Invest Radiol 1992;27:2-28.
14. Weibull H, Bergqvist D, Jonsson K, Carlsson S, Takolander R. Analysis of complications after percutaneous transluminal angioplasty of renal artery stenoses. Eur J Vasc Surg 1987;1:77-84.
15. Martin LG, Rees CR, O'Bryant T. Percutaneous angioplasty of the renal arteries. In: Strandness DE, Breda van A, eds. Vascular diseases: surgical and interventional therapy. 3rd ed. New York, NY: Churchill Livingstone, 1994;721-741.
16. Leertouwer TC, Gussenhoven EJ, Bosch JL, et al. Stent placement for renal arterial stenosis: where do we stand? a meta-analysis. Radiology 2000;216:78-85.
17. Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-effectiveness in health and medicine. New York, NY: Oxford University Press, 1996;
18. Isles C, Main J, O'Connell J, et al. Survival associated with renovascular disease in Glasgow and Newcastle: a collaborative study. Scott Med J 1990;35:70-73.
19. Hankey GJ, Jamrozik K, Broadhurst RJ, et al. Five-year survival after first-ever stroke and related prognostic factors in the Perth Community Stroke Study. Stroke 2000;31: 2080-2086.
20. Byrne C, Vernon P, Cohen JJ. Effect of age and diagnosis on survival of older patients beginning chronic dialysis. JAMA 1994;271: 34-36.
21. Iseki K, Kimura Y, Wakugami K, et al. Comparison of the effect of blood pressure on the development of stroke, acute myocardial infarction, and end-stage renal disease. Hypertens Res 2000;23:143-149.
22. Losinno F, Zuccalà A, Busato F, Zucchelli P. Renal artery angioplasty for renovascular hypertension and preservation of renal function: long-term angiographic and clinical follow-up. AJR Am J Roentgenol 1994;162: 853-857.
23. Chabova V, Schirger A, Stanson AW, McKusick MA, Textor SC. Outcomes of atherosclerotic renal artery stenosis managed without revascularization. Mayo Clin Proc 2000; 75:437-444.
24. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. I. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-774.
25. Krijnen P, van Jaarsveld BC, Steyerberg EW, Man in 't Veld AJ, Schalekamp MA, Habbema JD. A clinical prediction rule for renal artery stenosis. Ann Intern Med 1998; 129:705-711.
26. Oostenbrink JB, Kooprnanschap MA, Rutten FF. Handleiding voor kostenonderzoek: methoden en richtlijnprijzen voor economische evaluates in de gezondheidszorg. Arnstelveen, the Netherlands: College voor zorgverzekeringen, 2000;
27. de Wit GA, Polder JJ, Jager KJ, de Charro FT. De maatschoppelijke kosten van nierziekten in Nederland. Tijdsehr Gezondheidswetenschappen 2001;79:49-54.
28. van Bergen PF,, Jonker JJ, van Hout BA, et al. Costs and effects of long-term oral anticoagulant treatment after myocardial infarction. JAMA 1995;273:925-928.
29. Bergman L, van der Meulen JH, Limburg M, Habbema JD. Costs of medical care after first-ever stroke in the Netherlands. Stroke 1995;26:1830-1836.
30. Kiiskinen U, Vartiainen E, Puska P, Aromaa A. Long-term cost and life-expectancy consequences of hypertension. J Hypertens 1998; 16:1103-1112.
31. Samsa GP, Matchar DB, Goldstein L, et al. Utilities for major stroke: results from a survey of preferences among persons at increased risk for stroke. Am Heart J 1998; 136:703-713.
32. Postulart D, Adang EM. Response shift and adaptation in chronically ill patients. Med Decis Making 2000;20:186-193.
33. Tsevat J, Goldman L, Lamas GA, et al. Functional status versus utilities in survivors of myocardial infarction. Med Care 1991;29: 1153-1159.
34. Lawrence WF, Fryback DG, Martin PA, Klein R, Klein BE. Health status and hypertension: a population-based study. J Clin Epidemiol 1996;49:1239-1245.
35. Bosch JL, Tetteroo E, Mali WP, Hunink MG; for the Dutch Iliac Stent Trial Study Group. Iliac arterial occlusive disease: cost-effectiveness analysis of stent placement versus percutaneous transluminal angioplasty. Radiology 1998;208:641-648.
36. Koopmanschap MA, van Ineveld BM. Towards a new approach for estimating indirect costs of disease. Soc Sci Med 1992;34: 1005-1010.
37. Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ 1995;14:171-189.
38. Koopmanschap MA, Rutten FF. A practical guide for calculating indirect costs of disease. Pharmacoeconomics 1996;10:460-466.
39. Farmacotherapeutisch Kompas 2000/2001. Amstelveen, the Netherlands: College voor zorgverzekeringen.
40. The EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
41. Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53-72.
42. Dolan P, Gudex C, Kind P, Williams A. A social tariff for EuroQol: results from a UK general population survey - discussion paper 138. York, United Kingdom: University of York, Centre for Health Economics, 1995;
43. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-1108.
44. Helin KH, Tikkanen I, Von Knorring JE, et al. Screening for renovascular hypertension in a population with relatively low prevalence. J Hypertens 1998;16:1523-1529.
45. Nelemans PJ, Kessels AG, de Leeuw P, de Haan M, van Engelshoven J. The cost-effectiveness of the diagnosis of renal artery stenosis. Eur J Radiol 1998;27:95-107.
46. Radermacher J, Brunkhorst R. Diagnosis and treatment of renovascular stenosis: a cost-benefit analysis. Nephrol Dial Transplant 1998;13:2761-2767.
47. Blaufox MD, Middleton ML, Bongiovanni J, Davis BR. Cost efficacy of the diagnosis and therapy of renovascular hypertension. J Nucl Med 1996;37:171-177.
48. Lawrence WF, Grist TM, Brazy PC, Fryback DG. Magnetic resonance angiography in progressive renal failure: a technology assessment. Am J Kidney Dis 1995;25:701-709.
49. Lévesque J, Lacourciere Y, Onrot JM, et al. Economic impact of an ultrasonographic contrast agent on the diagnosis and initial management of patients with suspected renal artery stenosis. Can Assoc Radiol J 2002; 53:228-236.
50. Carlos RC, Axelrod DA, Ellis JH, Abrahamse PH, Fendrick AM. Incorporating patient-centered outcomes in the analysis of cost-effectiveness: imaging strategies for renovascular hypertension. AJR Am J Roentgenol 2003;181:1653-1661.
51. Visser K, de Vries SO, Kitslaar PJ, van Engelshoven JM, Hunink MG. Cost-effectiveness of diagnostic imaging work-up and treatment for patients with intermittent claudication in the Netherlands. Eur J Vasc Endovasc Surg 2003;25:213-223.
52. van Hout B, Bonsel G, Habbema D, van der Maas P, de Charro F. Heart transplantation in the Netherlands: costs, effects and scenarios. J Health Econ 1993;12:73-93.
53. van Enckevort PJ, TenVergert EM, Bonsel GJ, et al. Technology assessment of the Dutch Lung Transplantation Program. Int J Technol Assess Health Care 1998;14:344-356.
54. Graham JD, Corso PS, Morris JM, Segui-Gomez M, Weinstein MC. Evaluating the cost-effectiveness of clinical and public health measures. Annu Rev Public Health 1998;19:125-152.
55. van Erkel AR, van den Hout WB, Pattynama PM. International differences in health care costs in Europe and the United States: do these affect cost-effectiveness of diagnostic strategies for pulmonary embolism? Eur Radiol 1999;9:1926-1931.
56. Bosch JL, Haaring C, Meyerovitz MF, Cullen KA, Hunink MG. Cost-effectiveness of percutaneous treatment of iliac artery occlusive disease in the United States. AJR Am J Roentgenol 2000;175:517-521.